The inability of Ranbaxy Laboratories to get its generic of heart drug Diovan to market for 18 months has been a boon for Novartis. Not so much for consumers.
written on 15.04.2014
Novartis' gain is consumers' $900M loss from stalled Ranbaxy generics
